About this Research Topic
Many challenges remain in CAR therapy for infectious viral diseases. This includes safety concerns associated with CAR-T therapies, problems with CAR-T cell trafficking and persistence, viral antigen escape, and viral latency. In this collection, we would like to showcase new advances in CAR immune therapy for infectious viral diseases that tackle these problems.
In this collection, we would like to invite manuscripts related to CAR immune therapy for infectious viral diseases. We are interested in Original Research, Case Report, Review/Mini-review and Perspective articles, focusing on but not limited to the following areas:
• Novel CAR designs to prevent viral escape
• Engineered immune modulators to improve safety, and/or increase CAR-T efficacy and prevent/restore exhaustion
• Novel antigens targeting
• CAR immune cells engineering beyond T cells
• Reports on preclinical studies and clinical trials
Dr. Scott Kitchen is cofounder of CDR3 Therapeutics, which is involved in the commercialization of immunotherapy approaches. The other Topic Editors declare no potential competing interests.
Keywords: CAR immunotherapy, infectious viral diseases, CAR-T, viral escape, HIV, HBV, EBV
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.